ACRV (Acrivon Therapeutics) Insider Ownership: 7.73 % (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRV Acrivon Therapeutics Inc ACRV
34 GF Score
Price $2.14
! 3 Warning Signs
View Full Analysis

What is Acrivon Therapeutics Insider Ownership?

Acrivon Therapeutics ACRV +4.40% 34 Insider Ownership is 7.73 % as of Aug. 19, 2026. GuruFocus rates ACRV with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Acrivon Therapeutics's insider ownership is 7.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Acrivon Therapeutics's Institutional Ownership is 37.94%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Acrivon Therapeutics's Float Percentage Of Total Shares Outstanding is 67.00%.

Acrivon Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Acrivon Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrivon Therapeutics Insider Ownership Chart

Acrivon Therapeutics Historical Data

The historical data trend for Acrivon Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 9.51 9.47 9.47 9.47 9.43 9.49 9.49 7.73 7.73 7.73
ACRV
34GF Score
Acrivon Therapeutics Inc ACRV
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acrivon Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 7.73 % mean?
Acrivon Therapeutics (ACRV) has a Insider Ownership of 7.73 % as of Aug. 19, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Acrivon Therapeutics and its competitors.
Is Acrivon Therapeutics' Insider Ownership too high?
Acrivon Therapeutics' current Insider Ownership is 7.73 %. Overall, Acrivon Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Insider Ownership compare to SPRO and BSEM?
Acrivon Therapeutics' Insider Ownership of 7.73 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Acrivon Therapeutics and its competitors. Acrivon Therapeutics's current Insider Ownership is 7.73 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Insider Ownership of 7.73 %. The current Insider Ownership is 7.73 %. Acrivon Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Insider Ownership is 7.73 % as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrivon Therapeutics Business Description

Address 480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
34GF Score

Get the complete analysis for ACRV

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.14
Price